Sheba Initiates Clinical Trial to Evaluate Breakthrough Cancer Treatment

July 21, 2020

In a world’s first, Sheba is trying a completely novel approach to prolong the lives of stage 4 cancer patients who don’t respond to traditional drugs.

Sheba’s 40-patient clinical study will treat resistant metastatic melanoma, triple-negative breast cancer, renal cell carcinoma and non-small cell lung cancer patients.  In this trial, Sheba has teamed up with Immunicom to improve the efficacy of the immunotherapy drugs by using Immunicom’s LW-02 plasma filtration.

Professor Gal Markel, Principal Investigator of the clinical trial and Director of the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center was interviewed on the Armstrong Williams Show on July 18 broadcast on dozens of Sinclair Broadcasting affiliates nationwide.

Don't miss out.

Sign up our weekly newsletter for the latest updates on medical advances and humanitarian efforts of Israel.